Drug
Pemetrexed/Platinum
Pemetrexed/Platinum is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
33%
Ph phase_3
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 3Large-scale testing
1(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(3)
Detailed Status
Completed3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (50.0%)
Phase 31 (50.0%)
Trials by Status
completed3100%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_3
Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer
NCT01951482
completed
Emulation of the KEYNOTE-189 Trial Using Electronic Health Records
NCT05908799
completedphase_2
Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC
NCT01769066
Clinical Trials (3)
Showing 3 of 3 trials
NCT01951482Phase 3
Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer
NCT05908799
Emulation of the KEYNOTE-189 Trial Using Electronic Health Records
NCT01769066Phase 2
Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3